Imatinib Mesylate in Treating Patients With Salivary Gland Cancer

NCT00045669 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: imatinib mesylate

Sponsor

University Health Network, Toronto

Collaborators

[object Object]